ArticleVeterinary research communications2026
Changes in serological, inflammatory, and serum protein electrophoretic markers during ongoing meglumine antimoniate plus allopurinol therapy in canine leishmaniosis.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine leishmaniosis, caused by Leishmania infantum, is a vector-borne disease in which early treatment monitoring remains challenging. This prospective study evaluated short-term changes in serological, inflammatory, and serum protein electrophoretic parameters during first-line therapy with meglumine antimoniate plus allopurinol. Eighteen dogs with confirmed clinical disease were enrolled at diagnosis, and fifteen dogs completing all follow-up visits (Days 0, 7, 14, 21, and 29) were included. Infection was confirmed by compatible clinical and/or laboratory abnormalities, high anti-Leishmania antibody levels, and successful parasite isolation. Anti-Leishmania antibodies were quantified using in-house single-dilution and two-fold serial dilution ELISA; circulating immune complexes, C-reactive protein, a complete blood count, a biochemical profile, and serum protein electrophoresis were also assessed. Both ELISA methods showed a significant decline in antibody levels during treatment, with serial dilution ELISA showing greater discrimination among highly positive samples. C-reactive protein concentrations decreased significantly from diagnosis to Day 29, indicating reduced systemic inflammation. Serum protein electrophoresis showed significant increases in albumin and the albumin:globulin ratio, along with a significant decrease in gamma globulins. Circulating immune complexes concentrations remained stable. These findings support quantitative serology, C-reactive protein, and serum protein electrophoresis as useful tools for early monitoring of therapeutic response in clinical canine leishmaniosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.